Posted by Michael Wonder on 06 Dec 2022
SQZ Biotechnologies receives FDA fast track designation for its eAPC therapeutic candidate for treatment of HPV16 positive tumours
6 December 2022 - Stable disease observed in two out of four evaluable patients in eAPC Phase 1/2 trial including a pronounced pharmacodynamic response in a patient with prolonged stable disease.
SQZ Biotechnologies today announced that the US FDA has granted fast track designation for the company’s enhanced antigen presenting cell candidate for the treatment of HPV16 positive advanced or metastatic solid tumours.
